{"id":"8c7440e2-9aa8-5a1f-9ba7-d7cc2464be2a","stable_key":"f2ec2007-88ff-5a96-a73b-8b5085e9cea9:mbz-beats-vincristine","predicate":"reported_comparison","statement":"Comparing therapeutic efficacy against GL261 orthotopic tumours, mebendazole showed a significant increase in animal survival time whereas vincristine, even at a dose close to its maximum tolerated dose, failed to show any efficacy; vincristine does not penetrate well into brain tumour tissue and displays dose-limiting toxicities including peripheral neuropathy.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"positive","is_public":true,"mechanism_event_id":"2d4dd590-f0fc-5ba1-92f9-193b7b326448","mechanism_event_label":"Against brain tumours in mice it beat the microtubule drug already in clinical use, which cannot get into the brain.","subject":{"id":"f8582a13-fc2e-5127-a61f-5b0594e54069","slug":"mebendazole","display_name":"Mebendazole","entity_type_key":"drug"},"object":{"id":"be8f4ffd-348c-579b-9f79-38cf9dca6b47","slug":"vincristine","display_name":"Vincristine","entity_type_key":"drug"},"evidence_count":1,"mechanism_event":{"id":"2d4dd590-f0fc-5ba1-92f9-193b7b326448","stable_key":"f2ec2007-88ff-5a96-a73b-8b5085e9cea9:mbz-beats-vincristine-event","event_type":"biochemical_relationship","label":"Against brain tumours in mice it beat the microtubule drug already in clinical use, which cannot get into the brain.","description":"Comparing therapeutic efficacy against GL261 orthotopic tumours, mebendazole showed a significant increase in animal survival time whereas vincristine, even at a dose close to its maximum tolerated dose, failed to show any efficacy; vincristine does not penetrate well into brain tumour tissue and displays dose-limiting toxicities including peripheral neuropathy.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"ace31cb7-2519-519c-aa9b-5ebdd5bf437e","slug":"orthotopic-glioma-survival","display_name":"Survival of mice bearing orthotopic glioma","entity_type_key":"cellular_process"},"role":"measured_endpoint","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"f8582a13-fc2e-5127-a61f-5b0594e54069","slug":"mebendazole","display_name":"Mebendazole","entity_type_key":"drug"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"be8f4ffd-348c-579b-9f79-38cf9dca6b47","slug":"vincristine","display_name":"Vincristine","entity_type_key":"drug"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/mebendazole-research/28386621.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"20ef610d6b4a341f8a0a3f731bbea5477badbee517062c303bbf1075f3a29865\", \"start_char\": 0, \"end_char\": 1788, \"text_sha256\": \"20ef610d6b4a341f8a0a3f731bbea5477badbee517062c303bbf1075f3a29865\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Concentration-matched comparison of viability, microtubule polymerisation and metaphase arrest, with NCI COMPARE analysis and a head-to-head animal comparison against vincristine","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Mebendazole against vincristine close to its maximum tolerated dose in orthotopic GL261 tumours","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Tests whether the anticancer effect is the microtubule effect by matching concentrations across three assays, which most repurposing studies do not do.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Mebendazole research collection; topical membership is not evidence of a direct clinical effect, and mebendazole is recorded separately from albendazole, from the benzimidazole class and from its own crystal forms.","comparator":null,"unit":null,"notes":"","entity":{"slug":"mebendazole","display_name":"Mebendazole","entity_type_key":"drug"}},{"dimension":"organism","value_text":"Mouse","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"Against brain tumours in mice it beat the microtubule drug already in clinical use, which cannot get into the brain.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[mbz-p28386621] Repurposing Mebendazole as a Replacement for Vincristine for the Treatment of Brain Tumors. (2017). https://pubmed.ncbi.nlm.nih.gov/28386621/ DOI: 10.2119/molmed.2017.00011","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Glioblastoma","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"2171a7dd-5945-515e-871b-f151942d3f0f","evidence_kind":"source_excerpt","locator":"Lines 511-522","start_line":511,"end_line":522,"excerpt":"### mbz-beats-vincristine\nComparing therapeutic efficacy against GL261 orthotopic tumours, mebendazole showed a significant increase in animal survival time whereas vincristine, even at a dose close to its maximum tolerated dose, failed to show any efficacy; vincristine does not penetrate well into brain tumour tissue and displays dose-limiting toxicities including peripheral neuropathy.\nCondition category: normal\nnutrient_topic: Mebendazole research collection; topical membership is not evidence of a direct clinical effect, and mebendazole is recorded separately from albendazole, from the benzimidazole class and from its own crystal forms.\nplain_language: Against brain tumours in mice it beat the microtubule drug already in clinical use, which cannot get into the brain.\norganism: Mouse\ntissue_or_cell_type: Glioblastoma\nexperimental_model: Concentration-matched comparison of viability, microtubule polymerisation and metaphase arrest, with NCI COMPARE analysis and a head-to-head animal comparison against vincristine\nlimitations: Tests whether the anticancer effect is the microtubule effect by matching concentrations across three assays, which most repurposing studies do not do.\nexposure: Mebendazole against vincristine close to its maximum tolerated dose in orthotopic GL261 tumours\nevidence_span: {\"source_cache\": \"artifacts/mebendazole-research/28386621.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"20ef610d6b4a341f8a0a3f731bbea5477badbee517062c303bbf1075f3a29865\", \"start_char\": 0, \"end_char\": 1788, \"text_sha256\": \"20ef610d6b4a341f8a0a3f731bbea5477badbee517062c303bbf1075f3a29865\"}\n[mbz-p28386621] Repurposing Mebendazole as a Replacement for Vincristine for the Treatment of Brain Tumors. (2017). https://pubmed.ncbi.nlm.nih.gov/28386621/ DOI: 10.2119/molmed.2017.00011","model_system":"Concentration-matched comparison of viability, microtubule polymerisation and metaphase arrest, with NCI COMPARE analysis and a head-to-head animal comparison against vincristine","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [mbz-p28386621] Repurposing Mebendazole as a Replacement for Vincristine for the Treatment of Brain Tumors. (2017). https://pubmed.ncbi.nlm.nih.gov/28386621/ DOI: 10.2119/molmed.2017.00011","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"06104773-03d0-5e5c-b9da-eb484e7be657","stable_key":"import-f2ec2007-88ff-5a96-a73b-8b5085e9cea9","title":"Mebendazole: the tubulin it binds, why that is selective, the crystal form that decides whether any of it works, and the off-target that became an oncology programme (2026-09-22)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"58b652636677e5033fd1dd555744485fcef18f21a97dcf68723fe072b656f413","revision_id":"a2cd9c22-0549-52ca-a653-8a0c2362ec85","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}